NCT03640403View on ClinicalTrials.gov

Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania

PHASE3CompletedINTERVENTIONAL
Enrollment

1,555

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2021

Conditions
Malaria,FalciparumAnemia
Interventions
DRUG

Dihydroartemisinin-piperaquine

Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.

DRUG

Artesunate-amodiaquine

Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.

Trial Locations (1)

255

National Institute for Medical Research, Tanga

All Listed Sponsors
collaborator

Universiteit Antwerpen

OTHER

lead

National Institute for Medical Research, Tanzania

OTHER_GOV

NCT03640403 - Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania | Biotech Hunter | Biotech Hunter